Neoplasm by Special Category

TYMS copy number was lower in clinical samples responding to pemetrexed in combination with platinum (n=25). The same was found in 17 cell lines.

PMID 23645741 · Kasai et al., 2013 · Open in CIViC

Reduced TYMS expression by shRNA increased fluorouracil cytotoxicity in HCT-116, HT-29, and SW620 colorectal cancer cells, with approximately 3- to 8-fold enhancement of drug sensitivity.

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

mRNA expression of thymidylate synthase (TYMS) in 62 NSCLC patients correlated with response rate to pemetrexed mono- or combination therapy. Response rate with low TYMS expression was 0.29 compared w… (full text at CIViC)

PMID 26502926 · Chamizo et al., 2015 · Open in CIViC

mRNA levels of TYMS, DHFR and GARFT were assessed (rt-PCR) in 50 patient samples of NSCLC. TYMS mRNA levels were lower in responders compared to non-responders to pemetrexed (1.671 ± 0.844 versus 5.97… (full text at CIViC)

PMID 23060591 · Shimizu et al., 2012 · Open in CIViC

499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The TYMS rs34743033 tandem repeat polymorphism was the only significant predictor of stomatitis in a multip… (full text at CIViC)

PMID 23652803 · Radtke et al., 2013 · Open in CIViC

49 tumor specimens from 268 NSCLC patients treated with pemetrexed were evaluated for expression of TYMS and DHFR by IHC and compared to treatment outcomes. Patients with low TS (≤150) expression had … (full text at CIViC)

PMID 21367480 · Chen et al., 2011 · Open in CIViC

Case report of a patient with metastatic prostate cancer and underexpression of TYMS who showed a nonspecified response to pemetrexed for at least 4 months.

PMID 24782778 · Russell et al., 2014 · Open in CIViC

In a large study of patients with primary myelofibrosis evaluating mutations associated with anemia, 457 patients were evaluated for U2AF1 mutations. U2AF1 mutations were significantly associated with… (full text at CIViC)

PMID 27058230 · Barraco et al., 2016 · Open in CIViC

Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF Q157P/R mutations and those who harbor wild type U2AF.

PMID 23029227 · Qian et al., 2012 · Open in CIViC

After adjusting for age and cancer stage, presence of U2AF mutation such as Q157P/R is prognostic for poorer survival outcomes in patients with MDS.

PMID 23861105 · Wu et al., 2013 · Open in CIViC

Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF S34Y/F mutations and those who harbor wild type U2AF.

PMID 23029227 · Qian et al., 2012 · Open in CIViC

After adjusting for age and cancer stage, the presence of U2AF mutations such as S34Y/F are prognostic for poorer survival outcomes in patients with MDS.

PMID 23861105 · Wu et al., 2013 · Open in CIViC

This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Some concerns about the validity of the results have been expressed in subs… (full text at CIViC)

PMID 28985567 · Reddy et al., 2017 · Open in CIViC

Through a meta-analysis of exome and whole genome sequencing data, this study identified 18 genes that were significantly enriched for mutations in MCL including UBR5. This gene has also been reported… (full text at CIViC)

PMID 32160292 · Pararajalingam et al., 2020 · Open in CIViC

UBTF tandem duplications frequently found in patients with relapsed AML.

PMID 35176137 · Umeda et al., 2022 · Open in CIViC

shRNA-mediated reduction of UCK2 expression significantly sensitized HCT-116, HT-29, and SW620 colorectal cancer cells to fluorouracil, decreasing IC50 approximately 3- to 6-fold.

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

Using next-generation DNA and RNA sequencing, three cases harboring NTRK fusions were identified in a cohort of 113 osteosarcomas (including both primary tumors and metastases). Each of the three case… (full text at CIViC)

PMID 32022484 · Ameline et al., 2020 · Open in CIViC

The FDA approved package insert for Belinostat recommends dose adjustment for UGT1A1*28 allele homozygotes.

PMID 26313268 · Goey et al., 2016 · Open in CIViC

In a phase 1 trial belinostat (400-800mg/m2/24h) was administered to 25 patients in combination with cisplatin and etoposide. Endpoints were associations between genotype of UGT1A1 and pharmacokinetic… (full text at CIViC)

PMID 26313268 · Goey et al., 2016 · Open in CIViC

Colorectal cancer cell lines were evaluated for response to the HSP90 inhibitor ganetespib. Correlating cell line-specific IC50s with the corresponding gene expression patterns revealed a possible re… (full text at CIViC)

PMID 25210794 · Landmann et al., 2014 · Open in CIViC

shRNA-mediated reduction of UMPS expression increased resistance to fluorouracil by approximately twofold in HCT-116 and SW620 colorectal cancer cells, as measured by increased IC50.

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

Reduction of UNG expression by shRNA significantly sensitized all three colorectal cancer cell lines to fluorouracil. Across the UNG, NME1, and RRM1 experiments, IC50 decreases ranged from approximate… (full text at CIViC)

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. The USP25-JAK2 fusion is rare; this study involve… (full text at CIViC)

PMID 28408464 · Reshmi et al., 2017 · Open in CIViC

Described in multiple genome-wide studies of BL

PMID 30617194 · Grande et al., 2019 · Open in CIViC

The study showed association of the ABL1 fusions with partner genes other than BCR with a specific molecular/genetic subtype of B-lymphoblastic leukemia characterized by the expression signature simil… (full text at CIViC)

PMID 25207766 · Roberts et al., 2014 · Open in CIViC

The study showed that in B-ALL the the presence of ABL2 fusions with different partner genes is diagnostic for the so-called BCR-ABL1-like (or Philadelphia (Ph)-like) molecular subtype of B-ALL. Ph-l… (full text at CIViC)

PMID 25207766 · Roberts et al., 2014 · Open in CIViC

The RCSD1-ABL2 fusion was identified in a 5 yo boy with Ph-like B-ALL and Klinefelter syndrome. Following standard induction therapy the patient had an MRD of 1.2% in bone marrow, and continued to be … (full text at CIViC)

PMID 25207766 · Roberts et al., 2014 · Open in CIViC

In this Phase II trial of 87 patients (NCT01871805), alectinib was assayed for safety and efficacy in ALK positive NSCLC that had progressed on crizotinib. Of 69 patients with measurable disease, 35 a… (full text at CIViC)

PMID 26708155 · Shaw et al., 2016 · Open in CIViC

In a phase 3 trial, 303 patients with NSCLC with ALK fusion were randomly assigned to alectinib arm (N=152) or crizotinib arm (N=151). PFS was significantly longer with alectinib than with crizotinib … (full text at CIViC)

PMID 28586279 · Peters et al., 2017 · Open in CIViC